New combo aims to control myeloma relapse after transplant
NCT ID NCT03413800
First seen May 15, 2026 · Last updated May 17, 2026 · Updated 1 time
Summary
This study tested a two-step treatment for multiple myeloma that returned after a donor stem cell transplant. Ten adults received lenalidomide and dexamethasone, followed by infusions of donor immune cells, to boost the body's ability to fight the cancer. The goal was to improve disease control and delay progression, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montreal, Quebec, H1T2M4, Canada
Conditions
Explore the condition pages connected to this study.